Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.090
-0.060 (-5.22%)
At close: Mar 5, 2026, 4:00 PM EST
1.130
+0.040 (3.67%)
After-hours: Mar 5, 2026, 7:56 PM EST
Humacyte Employees
As of December 31, 2024, Humacyte had 220 total employees, including 218 full-time and 2 part-time employees. The number of employees increased by 35 or 18.92% compared to the previous year.
Employees
220
Change (1Y)
35
Growth (1Y)
18.92%
Revenue / Employee
$7,141
Profits / Employee
-$168,041
Market Cap
210.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 220 | 35 | 18.92% |
| Dec 31, 2023 | 185 | 21 | 12.80% |
| Dec 31, 2022 | 164 | 18 | 12.33% |
| Dec 31, 2021 | 146 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcturus Therapeutics Holdings | 176 |
| Voyager Therapeutics | 172 |
| Prelude Therapeutics | 131 |
| MediWound | 111 |
| Acumen Pharmaceuticals | 61 |
| Camp4 Therapeutics | 55 |
| Eledon Pharmaceuticals | 31 |
| Ovid Therapeutics | 23 |
HUMA News
- 3 days ago - Humacyte To Participate in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting - GlobeNewsWire
- 24 days ago - Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels - GlobeNewsWire
- 2 months ago - Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications - GlobeNewsWire
- 2 months ago - Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - GlobeNewsWire
- 2 months ago - Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair - GlobeNewsWire
- 2 months ago - Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital - GlobeNewsWire
- 3 months ago - Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results - GlobeNewsWire